Is Nuclear Factor κB an Attractive Therapeutic Target for Treating Cardiac Hypertrophy?
- 12 August 2003
- journal article
- Published by Wolters Kluwer Health in Circulation
- Vol. 108 (6) , 638-640
- https://doi.org/10.1161/01.cir.0000085362.40608.dd
Abstract
Background— Adrenergic receptor blockers used in the treatment of heart failure have distinct receptor affinity profiles. We hypothesized that α-adrenergic–blocking effects of carvedilol would limit vasoconstriction in response to adrenergic stimuli when compared with metoprolol.Keywords
This publication has 21 references indexed in Scilit:
- Activation of nuclear factor-κB is necessary for myotrophin-induced cardiac hypertrophyThe Journal of cell biology, 2002
- TNF‐α signal transduction in rat neonatal cardiac myocytes: definition of pathways generating from the TNF‐α receptorThe FASEB Journal, 2002
- Identification of IEX-1 as a Biomechanically Controlled Nuclear Factor-κB Target Gene That Inhibits Cardiomyocyte HypertrophyCirculation Research, 2002
- Retroinfusion of NFκB decoy oligonucleotide extends cardioprotection achieved by CD18 inhibition in a preclinical study of myocardial ischemia and retroinfusion in pigsGene Therapy, 2002
- NF-κB at the crossroads of life and deathNature Immunology, 2002
- The Cytoprotective Effects of the Glycoprotein 130 Receptor-coupled Cytokine, Cardiotrophin-1, Require Activation of NF-κBJournal of Biological Chemistry, 2001
- Effect of NF- κ B Inhibition on TNF- α -induced Apoptosis and Downstream Pathways in CardiomyocytesJournal of Molecular and Cellular Cardiology, 2001
- Cytoplasmic Signaling Pathways That Regulate Cardiac HypertrophyAnnual Review of Physiology, 2001
- Cardiac-specific Abrogation of NF- κ B Activation in Mice by Transdominant Expression of a Mutant Iκ B αJournal of Molecular and Cellular Cardiology, 2001
- The epidemiology of heart failure: The Framingham StudyJournal of the American College of Cardiology, 1993